Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
THAR 
Tharimmune Inc. (THAR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: THAR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.77% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.24M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 1.44 | 52 Weeks Range 0.95 - 9.08 | Updated Date 10/15/2025 |
52 Weeks Range 0.95 - 9.08 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -140.33% | Return on Equity (TTM) -340.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18775838 | Price to Sales(TTM) - |
Enterprise Value 18775838 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.32 | Shares Outstanding 6809214 | Shares Floating 2860413 |
Shares Outstanding 6809214 | Shares Floating 2860413 | ||
Percent Insiders 37.96 | Percent Institutions 6.14 |
Upturn AI SWOT
Tharimmune Inc.
Company Overview
History and Background
Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of therapeutic candidates for unmet medical needs in inflammatory diseases and immunology. It was founded to leverage a novel approach to modulating the immune system.
Core Business Areas
- Lead Compound Development: Focuses on the development of their lead compound, T-100, for treating various inflammatory conditions.
- Novel Therapeutic Pipeline Expansion: Identifying and developing new therapeutic candidates in the field of immunology and inflammation. Their main candidate is called T100
Leadership and Structure
Details on the leadership team and specific organizational structure were difficult to source
Top Products and Market Share
Key Offerings
- T-100: T-100 is Tharimmune's lead compound in development for treating various inflammatory diseases. Precise market share data or revenue for T-100 is not publicly available, as it is still in clinical development. Competitors vary depending on the specific inflammatory condition being targeted.
Market Dynamics
Industry Overview
The biotechnology industry, particularly the segment focused on inflammation and immunology, is characterized by high growth potential, intense competition, and substantial R&D investment.
Positioning
Tharimmune Inc. aims to establish itself as a player in the immunology and inflammation space by developing novel therapeutic candidates like T-100 that target unmet medical needs. Their competitive advantage, if they achieve one, would stem from efficacy and a favorable safety profile relative to existing treatments.
Total Addressable Market (TAM)
The TAM for inflammatory disease treatments is substantial, reaching hundreds of billions of dollars globally. Tharimmune's positioning within this TAM is still nascent, as it relies on the successful development and commercialization of its pipeline products.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (T-100)
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Early-stage clinical development
- Limited financial resources
- Dependence on T-100 success
- Lack of publicly available leadership details
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Growing market for immunology therapies
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- PFE
Competitive Landscape
Tharimmune Inc. faces intense competition from established pharmaceutical companies with significantly greater resources and established product portfolios. Success hinges on proving the efficacy and safety of their novel therapeutic approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable at this stage of development
Future Projections: Future growth depends on the successful development and commercialization of their product candidates.
Recent Initiatives: Recent initiatives are focused on clinical trials for T-100.
Summary
Tharimmune is a high-risk, high-reward clinical-stage biotech company developing therapies for inflammatory diseases. Its success is largely dependent on the successful development of T-100. It's an early-stage company and needs to be watched closely for its clinical trial results, potential partnerships, and how effectively it navigates the competitive and regulatory landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tharimmune Inc.
Exchange NASDAQ | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2022-01-12 | CEO & Director Mr. Sireesh Appajosyula Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.tharimmune.com |
Full time employees 2 | Website https://www.tharimmune.com | ||
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.